Introduction and Background

Coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by the novel “severe acute respiratory syndrome coronavirus-2” (SARS-CoV-2) and is rapidly spreading worldwide. This review is designed to highlight the most common clinical features and computed tomography (CT) signs of patients with COVID-19 and to elaborate the most significant signs indicative of COVID-19 diagnosis. This review involved five original articles with both clinical and radiological features of COVID-19 published during Jan and Mar 2020. In this review, the most frequent symptoms of COVID-19 were fever and cough. Myalgia, fatigue, sore throat, headache, diarrhea, and dyspnea were less common manifestations. Nausea and vomiting were rare. Ground-glass opacity (GGO) was the most common radiological finding on CT, and mixed GGO with consolidation was reported in some cases. In addition, elevated C-reactive protein and lymphopenia are the pertinent laboratory findings of COVID-19. CT is an effective and important imaging tool for both diagnosis and follow-up COVID-19 patients with varied features, duration, and course of the disease. Bilateral GGOs, especially in the periphery of the lungs with or without consolidation, are the hallmark of COVID-19.

Keywords: Clinical manifestations, COVID-19, CT features, fever, ground-glass opacity

Access this article online

Quick Response Code:
Website:
www.jfmpc.com

DOI:
10.4103/jfmpc.jfmpc_1985_20

How to cite this article: Alshoabi SA, Alhazmi FH, Abdulaal OM, Gameraddin MB, Algaberi AK, Hamid AM, et al. Frequent clinical and radiological manifestations of the Novel SARS-CoV-2: A review article. J Family Med Prim Care 2021;10:122-6.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Received: 25-09-2020
Revised: 03-12-2020
Accepted: 16-12-2020
Published: 30-01-2021
(1) Mild, patients with no or mild symptoms and no pneumonia on medical imaging, (2) Moderate, patients with symptoms and fever with pneumonia on clinical and medical imaging, (3) Severe, patients with respiratory distress (respiration rate >30 cycle/min) or oxygen saturation at a resting state <93% or lesion progress more than 50% of the lungs within 48 h on medical imaging, or PaO2/FiO2 <300 mmHg, and (4) Critical, patients with respiratory failure or shock or other multiorgan failure and need intensive care.[8] According to the sixth edition of the official “guidelines for the diagnosis and treatment of COVID-19” declared by the NHC of China, computed tomography (CT) is an effective and important screening tool to diagnose, monitor progression, and evaluate treatment effectiveness. Bilateral ground-glass opacities (GGOs) in the peripheral regions of the lungs with or without consolidation are the hallmark of COVID-19. Diverse CT features like crazy-paving pattern, reverse-halo sign, and airway changes and pleural changes can be present.[7] Features of COVID-19 start to appear on CT in 4–7 days from the onset of the initial clinical manifestations and subsequently appear in all stages of the disease.[9] Significant correlations are found between the severity of clinical manifestations and the severity of lung involvement on CT.[9] The American College of Radiology and the European society of radiology (ESR) recommended against the use of chest CT as a widespread screening tool for patients with COVID-19, including patients with no or mild symptoms. The “Real-time reverse transcription polymerase chain reaction” (RT-PCR) is considered as a standard diagnostic test for patients with COVID-19.[10]

The Dutch Radiological Society provided COVID-19 Reporting and Data system (CO-RADS) as a categorical CT assessment scheme for the level of suspicion of lung involvement in patients with moderate to severe symptoms of COVID-19 on a scale ranges from 0 to 6 as follows: (1) CO-RADS 0: no suspicion on normal CT, (2) CO-RADS 1: low suspicion when CT abnormalities are consistent with other infections, (3) CO-RADS 2: intermediate suspicion when CT abnormalities are compatible but unsure of COVID-19, (4) CO-RADS 4: high suspicion when CT abnormalities suspicious for COVID-19, (5) CO-RADS 5: very high suspicion when CT abnormalities are typical of COVID-19, (6) CO-RADS 6: proven by PT-PCR positive for COVID-19. If CT is technically insufficient for assigning the score, this is categorized as CO-RADS 0.[11]

This article was designed to summarize and highlight the most common clinical features and radiological signs seen on the CT of patients with COVID-19 and to elaborate the most significant clinical and radiological signs indicative of COVID-19 diagnosis. This review involved five original articles published between January and March 2020. Inclusion criteria involved the original articles interested in both the clinical and radiological features of COVID-19. We excluded review articles, case reports, articles interested only with clinical or radiological manifestations or with other ideas, articles focused only on a specific point, and articles available in other languages. Overall, five articles that met the inclusion criteria involved in this review.[12-14] The diagnosis of patients with COVID-19 was confirmed with PT-PCR in all cases of the involved studies. This article elaborates the most frequent features of COVID-19 for primary care physicians and family care doctors to be alert for detecting the disease as early as possible and to avoid bad complications resulting from delayed diagnosis during the pandemic.

**Review**

**Clinical manifestation**

In this review, the most common symptoms of COVID-19 were fever then cough [Table 1].

Fever was reported as the presenting symptom in 82%, 98%, 98.5%, 86.7%, and 83% and cough was reported in 61%, 76%, 59.4%, 78.3%, and 82% of patients in similar previous studies.[17-21] However, the less common clinical features of COVID-19 were fatigue, myalgia, sore throat, headache, diarrhea,

| Table 1: Common Clinical manifestations of COVID-19 |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Author**      | **Han et al., 2020[12]** | **Zhao et al., 2020[13]** | **Xu et al., 2020[14]** | **Xu et al., 2020[14]** | **Lomoro et al., 2020[15]** |
| **Study date**  | From Jan 4-Feb 3, 2020 | NA              | From Jan-Feb 2020    | From Jan 23-Feb 4, 2020 | From Feb 15-Mar 15, 2020 |
| **Patients (n)**| 108              | 101             | 50                  | 90                  | 58               |
| **Age (range) (Mean)** | 21-90           | 17-75 (44.44)   | 3-85 (43.9±16.8)    | 18-86 (50)          | 18-98 (66.3±16.6) |
| **Gender (m)**  | 38 (35.2)        | 56 (55.4)       | 29 (58%)            | 39 (43)             | 36               |
| **Fever**       | 94 (87)          | 79 (78.2)       | 43 (86)             | 70 (78)             | 58 (100)         |
| **Cough**       | 65 (60)          | 63 (62.4)       | 20 (40)             | 57 (63)             | 33 (37)          |
| **Sore throat** | 14 (13)          | 12 (11.9)       | 4 (8)               | 23 (26)             | NA               |
| **Headache**    | 14 (13)          | NA              | 5 (10)              | 4 (4)               | NA               |
| **Dyspnea**     | NA               | 1 (1)           | 4 (8)               | 24 (41)             | NA               |
| **Myalgia**     | 12 (11)          | 0 (0.0)         | 8 (16)              | 25 (28)             | 0 (0.0)          |
| **Fatigue**     | 42 (39)          | 0 (0.0)         | 8 (16)              | 19 (21)             | 18 (31)          |
| **Myalgia or fatigue** | 0 (0.0) | 17 (16.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Diarrhea**    | 15 (14)          | 3 (3)           | NA                  | 5 (6)               | NA               |
| **Nausea/vomiting** | NA             | 2 (2)           | NA                  | 7 (8)               | NA               |
| **↓ lymphocyte** | 65 (60)          | NA              | 14 (28)             | 48 (83)             | NA               |
| **↑ CRP**       | NA               | NA              | 26 (52)             | 38 (42)             | 56 (96.5)        |

COVID-19=Corona virus disease 2019, CRP=C‑reactive protein (normal range=0‑10 mg/liter), ↓ =decrease, ↑ =elevated, NA=Not available
and dyspnea. Many previous studies reported these symptoms less common than fever and cough.\textsuperscript{[17,18,22]} Furthermore, nausea, vomiting, and other gastrointestinal symptoms were relatively rare clinical features of COVID-19. Previous studies reported these as rare manifestations of COVID-19.\textsuperscript{[23,24]}

In this review, elevated C-reactive protein (↑ CRP) is a laboratory marker of inflammation and decreased lymphocytes (lymphopenia) were the pertinent laboratory findings of COVID-19. These findings were reported in many previous studies.\textsuperscript{[25-27]}

**Radiological manifestations**

In this review, GGO [Figure 1] was the most common radiological finding on CT [Table 2].

Previous studies reported GGO as the radiological sign in 97.6%, 100%, and 77% of the cases.\textsuperscript{[20,27-29]} Table 2 shows that mixed GGO with consolidation [Figure 2] was the second most common radiological feature, which was reported as 59% and 50% in previous studies.\textsuperscript{[29,30]}

Here, the CT findings were peripheral in 67.5% of the cases and reported as 89%, 86%, 75%, and 76% in previous studies.\textsuperscript{[27,29-31]}

In addition, a crazy-paving pattern [Figure 3] was the third most common radiological feature in this review; however, previous studies reported crazy paving in 36%, 29%, and 19.5% of the patients.\textsuperscript{[20,26,32]}

Furthermore, here pleural effusion was reported in 6.5% of cases, and it was reported as a rare finding (3%) in previous studies.\textsuperscript{[27,33]} Lymphadenopathy was reported in 2.4% in this review. However, lymphadenopathy was reported as a common finding (58%) in a previous study in Italy,\textsuperscript{[27]} and a rare finding in multiple previous studies.\textsuperscript{[28,33]}

El Homsi et al. reported that CT findings change with stages of COVID-19: (1) Early stage (the first two days), 56% of patients have negative CT; however, GGO was found in 44% and consolidation in the remaining 17%; (2) Intermediate stage (3–5 days), GGO was found in 88% and consolidation in 55%; bilaterally in 76% and peripherally in 64%; (3) Late-phase (6–12 days), GGO was found in 88% and consolidation in 60% of the cases; bilateral in 88% and peripheral consolidation in 85%.

**Table 2: Common Radiological signs of the involved patients (Pattern and distribution)**

| Author                  | Han et al., 2020\textsuperscript{[12]} | Zhao et al., 2020\textsuperscript{[13]} | Xu et al., 2020\textsuperscript{[14]} | Xu et al., 2020\textsuperscript{[15]} | Lomoro et al., 2020\textsuperscript{[16]} |
|-------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| Patients with CT (n)    | 108                                   | 93                                    | 41                                    | 90                                    | 42                                    |
| GGO                     | 65 (60)                               | 87 (86.1)                             | 30 (73.17)                            | 65 (72)                               | 15 (35.7)                             |
| Mixed GGO               | 44 (41)                               | 65 (64.4)                             | 25 (60.97)                            | NA                                    | 25 (59.5)                             |
| Consolidation           | 6 (5.55)                              | 44 (43.6)                             | 15 (36.58)                            | 12 (13)                               | 0 (0.0)                               |
| Crazy-paving            | 43 (40)                               | NA                                    | NA                                    | 11 (12)                               | 24 (57.1)                             |
| Pleural effusion        | 0 (0.0)                               | 14 (13.9)                             | 4 (9.75)                              | 4 (4)                                 | 3 (7.1)                               |
| Lymphadenopathy         | 0 (0.0)                               | 1 (1)                                 | 1 (2.43)                              | 1 (1)                                 | 6 (14.3)                              |
| Peripheral              | 97 (90)                               | 88 (87.1)                             | NA                                    | 46 (51)                               | 27 (64.3)                             |
| Central                 | 2 (2)                                 | 1 (1)                                 | NA                                    | NA                                    | 1 (2.4)                               |
| Mixed                   | 9 (8)                                 | NA                                    | NA                                    | NA                                    | 12 (28.6)                             |
Zheng et al. reported that CT features differ at various stages of COVID-19—early stage, progression stage, and absorption stage. Bhandari et al. reported that CT features of COVID-19 vary with the duration and course of the disease. GGO is high in the early stages and low in the late stages. Bernheim et al. reported that lung involvement was bilateral in 28%, 76%, and 88% in the early, intermediate, and late stages, respectively.

Ultimately, CT is crucial and provides an effective diagnosis of COVID-19. In patients with clinical features of COVID-19, low-dose CT can provide a diagnosis with comparable sensitivity to PT-PCR and high specificity to distinguish it from other similar clinical diseases. CT sensitivity for the diagnosis of COVID-19 increases after the fifth day of symptoms. CT is a fast, adequate, and reliable diagnostic modality to refer patients with COVID-19 for hospitalization when the response of PT-PCR is late.

**Conclusions**

Fever and cough are the most common clinical features of COVID-19. Fatigue, myalgia, sore throat, headache, diarrhea, and dyspnea are less common clinical manifestations. Nausea, vomiting, and other gastrointestinal symptoms are relatively rare. Elevated C-reactive protein and lymphopenia are the pertinent laboratory findings of COVID-19. CT is an effective and important imaging tool for the diagnosis and follow-up of COVID-19 with varied features, duration, and course of the disease. Bilateral GGOs, especially in the peripheral lungs, with or without consolidation, are the hallmark of COVID-19.

**Key messages**

1. Fever and cough are the frequent clinical features for diagnosis of COVID-19.
2. Bilateral GGOs, especially in the peripheral lungs, with or without consolidation, are the hallmark of COVID-19.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. Can Chinese medicine be used for prevention of coronavirus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med 2020;26:243-50.
2. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health 2020;13:667-73.
3. Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020;87:281-6.
4. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382:970-1.
5. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020;35:1549-59.
6. Li W, Fang Y, Liao J, Yu W, Yao L, Cui H, et al. Clinical and CT features of the COVID-19 infection: Comparison among four different age groups. Eur Geriatr Med 2020;11:843-50.
7. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): A pictorial review. Eur Radiol 2020;30:4381-9.
8. Zhang Y, Liu Y, Gong H, Wu L. Quantitative lung lesion features and temporal changes on chest CT in patients with common and severe SARS-CoV-2 pneumonia. PLoS One 2020;15:e0236858.
9. Zhou H, Xu K, Shen Y, Fang Q, Chen F, Sheng J, et al. Coronavirus disease 2019 (COVID-19): Chest CT characteristics benefit to early disease recognition and patient classification - a single center experience. Ann Transl Med 2020;8:679.
10. El Homsi M, Chung M, Bernheim A, Jacobs A, King MJ, Lewis S, et al. Review of chest CT manifestations of COVID-19 infection. Eur J Radiol Open 2020;7:100239.
11. Prokop M, van Everdingen W, van Rees Vellinga T, Quaresim Vanden H, Stöger L, Beenen L, et al. CO-RADS: A categorical CT assessment scheme for patients suspected of having COVID-19 definition and evaluation. Radiology 2020;296:E97-104.
12. Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia. AJR Am J Roentgenol 2020;215:338-43.
13. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: A multicenter study. AJR Am J Roentgenol 2020;214:1072-7.
14. Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect 2020;80:394-400.
15. Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020;47:1275-80.
16. Lomoro P, Verde F, Zerboni F, Simonetti C, Borghi C, Fachinetti C, et al. COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: Single-center study and comprehensive radiologic literature review. Eur J Radiol Open 2020;7:100231.
17. Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, et al. Imaging characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
20. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, Li C. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol 2020;55:327-31.

21. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.

22. Liu XH, Lu SH, Chen J, Xia L, Yang ZG, Charles S, et al. Clinical characteristics of foreign-imported COVID-19 cases in Shanghai, China. Emerg Microbes Infect 2020;9:1230-2.

23. Liu XH, Lu SH, Chen J, Xia L, Yang ZG, Charles S, et al. Clinical characteristics of COVID-19 patients with gastrointestinal symptoms: An analysis of seven patients in China. Front Med (Lausanne) 2020;7:308.

24. Yang X, Zhao J, Yan Q, Zhang S, Wang Y, Li Y. A case of COVID-19 patient with the diarrhea as initial symptom and literature review. Clin Res Hepatol Gastroenterol 2020. doi: 10.1016/j.clinre.2020.03.013.

25. Ghayda RA, Lee J, Lee JY, Kim DK, Lee KH, Hong SH, et al. Correlations of clinical and laboratory characteristics of COVID-19: A systematic review and meta-analysis. Int J Environ Res Public Health 2020;17:5026.

26. Li T, Wang L, Wang H, Gao Y, Hu X, Li X, et al. Characteristics of laboratory indexes in COVID-19 patients with non-severe symptoms in Hefei City, China: Diagnostic value in organ injuries. Eur J Clin Microbiol Infect Dis 2020;39:2447-55.

27. Caruso D, Zerunian M, Polici M, Pucciarelli F, Polidori T, Rucci C, et al. Chest CT features of COVID-19 in Rome, Italy. Radiology 2020;296:E79-85.

28. Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, et al. Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features. Invest Radiol 2020;55:257-61.

29. Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging 2019 novel coronavirus (2019-nCoV) Pneumonia. Radiology 2020;295:210-7.

30. Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): Analysis of nine patients treated in Korea. Korean J Radiol 2020;21:494-500.

31. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 2020;215:87-93.

32. Ojha V, Mani A, Pandey NN, Sharma S, Kumar S. CT in coronavirus disease 2019 (COVID-19): A systematic review of chest CT findings in 4410 adult patients. Eur Radiol 2020;30:6129-38.

33. Zheng Q, Lu Y, Lure F, Jaeger S, Lu P. Clinical and radiological features of novel coronavirus pneumonia. J Xray Sci Technol 2020;28:391-404.

34. Bhandari S, Rankawat G, Bagarhatta M, Singh A, Singh A, Gupta V, et al. Clinico-radiological evaluation and correlation of CT chest images with progress of disease in COVID-19 patients. J Assoc Physicians India 2020;68:34-42.

35. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection. Radiology 2020;295:200463.

36. Schulze-Hagen M, Hübel C, Meier-Schroers M, Dreher M, Brokmann J, Kopp A, et al. Low-dose chest CT for the diagnosis of COVID-19. Dtsch Arztebl Int 2020;117:389-95.

37. Guillo E, Bedmar Gomez I, Dangeard S, Bennani S, Saab I, Tordjman M, et al. COVID-19 pneumonia: Diagnostic and prognostic role of CT based on a retrospective analysis of 214 consecutive patients from Paris, France. Eur J Radiol 2020;131:109209.

38. Ducray V, Vlachomitrou AS, Bouscanemb-Duchamp M, Si-Mohamed S, Goutard S, Mansuy A, et al. Chest CT for rapid triage of patients in multiple emergency departments during COVID-19 epidemic: Experience report from a large French university hospital. Eur Radiol 2020. 1-9. doi: 10.1007/s00330-020-07154-4.